ACT 541468

Drug Profile

ACT 541468

Alternative Names: ACT 541468

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 01 Jan 2017 Actelion initiates a phase I pharmacokinetics trial in Healthy volunteers in Germany (PO, Capsule) (NCT03017495)
  • 01 Nov 2016 Phase-II clinical trials in Insomnia (In the elderly) in USA, Germany (PO) (NCT02841709)
  • 01 Oct 2016 Phase-II clinical trials in Insomnia (In adults) in Sweden (PO) (NCT02839200)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top